Alibaba Health Information Technology Limited (ALBBY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALBBY steht fuer Alibaba Health Information Technology Limited, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 46/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Alibaba Health Information Technology Limited (ALBBY) Gesundheitswesen & Pipeline-Uebersicht
Alibaba Health Information Technology Limited is a leading healthcare company in China, providing pharmaceutical e-commerce, direct sales, and digital healthcare services. The company leverages its parent company's technology and platform to offer a comprehensive suite of healthcare solutions, including online pharmacies, medical consultations, and health management tools.
Investmentthese
Alibaba Health presents a compelling investment case due to its strategic positioning within China's rapidly expanding digital healthcare market. The company's integration with Alibaba's vast ecosystem provides a significant competitive advantage, driving user acquisition and engagement. With a P/E ratio of 31.49 and a profit margin of 5.8%, the company demonstrates profitability and growth potential. Key growth catalysts include the increasing adoption of online healthcare services in China and the expansion of Alibaba Health's service offerings. However, investors should be aware of regulatory risks and competition within the Chinese healthcare market. The company's high beta of 1.72 indicates higher volatility compared to the market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $12.50 billion, reflecting substantial investor confidence in the company's market position.
- P/E ratio of 31.49, indicating a premium valuation based on earnings, suggesting strong growth expectations.
- Profit margin of 5.8%, demonstrating the company's ability to generate profit from its revenue streams.
- Gross margin of 24.5%, reflecting the efficiency of its operations in managing the cost of goods sold.
- Beta of 1.72, indicating higher volatility compared to the market, which may appeal to risk-tolerant investors seeking higher returns.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong brand recognition and reputation.
- Integration with Alibaba's ecosystem.
- Extensive online and offline network.
- Proprietary technology and data analytics.
Schwaechen
- Reliance on Alibaba's ecosystem.
- Exposure to regulatory risks in China.
- Competition from other online healthcare platforms.
- Relatively low profit margin.
Katalysatoren
- Ongoing: Expansion of online pharmacy business driven by increasing internet penetration in China.
- Ongoing: Development of digital healthcare services, including online consultations and remote monitoring.
- Upcoming: Potential regulatory changes in China that could favor online healthcare platforms.
- Ongoing: Strategic partnerships with hospitals and clinics to integrate online and offline services.
Risiken
- Potential: Changes in government regulations regarding online pharmacies and healthcare services.
- Ongoing: Increased competition from other online healthcare platforms and traditional pharmacies.
- Potential: Data security and privacy concerns related to the collection and use of patient data.
- Potential: Economic slowdown in China that could impact consumer spending on healthcare products and services.
Wachstumschancen
- Expansion of Online Pharmacy Business: The increasing adoption of online pharmacies in China presents a significant growth opportunity for Alibaba Health. As consumers become more comfortable purchasing prescription drugs and healthcare products online, Alibaba Health can leverage its e-commerce platform and logistics network to capture a larger share of the market. The Chinese online pharmacy market is projected to reach $50 billion by 2028, offering substantial growth potential.
- Development of Digital Healthcare Services: Alibaba Health can further expand its digital healthcare services, such as online consultations, remote monitoring, and chronic disease management. These services address the growing demand for convenient and accessible healthcare solutions. The digital healthcare market in China is expected to reach $200 billion by 2027, driven by government support and increasing consumer adoption.
- Strategic Partnerships with Hospitals and Clinics: Collaborating with hospitals and clinics to integrate online and offline healthcare services can enhance Alibaba Health's service offerings and expand its reach. These partnerships can enable the company to provide a more comprehensive and integrated healthcare experience for patients. The market for integrated healthcare solutions is growing rapidly, driven by the need for more efficient and coordinated care.
- Leveraging Artificial Intelligence and Big Data: Utilizing AI and big data analytics to personalize healthcare recommendations, improve diagnosis accuracy, and optimize treatment plans can enhance the value of Alibaba Health's services. These technologies can also help the company identify emerging health trends and develop innovative solutions. The AI in healthcare market is projected to reach $34 billion by 2025, offering significant opportunities for innovation and growth.
- Geographic Expansion within China: Expanding its presence in Tier 2 and Tier 3 cities in China can enable Alibaba Health to reach a wider customer base and tap into underserved markets. These cities are experiencing rapid economic growth and increasing demand for healthcare services. The healthcare market in Tier 2 and Tier 3 cities is expected to grow at a faster rate than in Tier 1 cities, presenting a significant growth opportunity.
Chancen
- Expansion of online pharmacy business.
- Development of digital healthcare services.
- Strategic partnerships with hospitals and clinics.
- Leveraging AI and big data analytics.
Risiken
- Changes in government regulations.
- Increased competition from domestic and international players.
- Data security and privacy concerns.
- Economic slowdown in China.
Wettbewerbsvorteile
- Strong brand recognition and reputation in the Chinese healthcare market.
- Integration with Alibaba's vast ecosystem of users and technology infrastructure.
- Extensive network of online and offline pharmacies.
- Proprietary technology and data analytics capabilities.
Ueber ALBBY
Alibaba Health Information Technology Limited, formerly known as CITIC 21CN Company Limited, rebranded in September 2014 to align with its parent company, Alibaba Group. The company operates as an investment holding entity with a focus on pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services. Its primary market is Mainland China and Hong Kong. Alibaba Health offers a wide array of products, including prescription drugs, over-the-counter medications, nutritional supplements, and medical devices, accessible through its online stores on Tmall.com and its network of offline pharmacy outlets, catering to both business-to-customer (B2C) and business-to-business (B2B) segments. The company's e-commerce platform extends its offerings to include health food, sexual health products, contact lenses, and medical and healthcare services. Alibaba Health provides medical services such as checkups, testing, consultations, and vaccinations through various digital channels like Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. Furthermore, it engages in tracking services, network hospital operations, and the provision of internet and technical services related to healthcare, including the operation of internet hospitals and asset management.
Was das Unternehmen tut
- Operates online pharmacies selling prescription and over-the-counter drugs.
- Provides medical and healthcare services through digital channels.
- Offers health-related products, including nutritional supplements and medical devices.
- Manages an e-commerce platform for healthcare products and services.
- Engages in pharmaceutical direct sales to businesses and consumers.
- Provides tracking services for pharmaceutical products.
- Operates internet hospitals and provides related technical services.
Geschaeftsmodell
- Generates revenue through the sale of pharmaceutical products and healthcare services on its online platforms.
- Earns commissions from third-party vendors selling products on its e-commerce platform.
- Provides subscription-based healthcare services to consumers and businesses.
- Offers advertising and marketing services to healthcare companies.
Branchenkontext
Alibaba Health operates within the rapidly growing digital healthcare market in China. This market is driven by increasing internet penetration, rising healthcare costs, and government support for online healthcare initiatives. The competitive landscape includes both domestic players and international companies seeking to capitalize on the growing demand for digital healthcare solutions. Alibaba Health benefits from its affiliation with Alibaba Group, which provides a vast ecosystem of users and technology infrastructure. The company competes with other online pharmacies and healthcare platforms, such as JD Health and Ping An Good Doctor.
Wichtige Kunden
- Individual consumers seeking pharmaceutical products and healthcare services.
- Hospitals and clinics purchasing pharmaceutical products and healthcare solutions.
- Businesses offering healthcare benefits to their employees.
- Healthcare companies seeking to market their products and services.
Finanzdaten
Chart & Info
Alibaba Health Information Technology Limited (ALBBY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ALBBY verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ALBBY.
Kursziele
Wall-Street-Kurszielanalyse fuer ALBBY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ALBBY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Difan Shen
CEO
Difan Shen is the CEO of Alibaba Health Information Technology Limited. Information regarding his detailed career history, education, and previous roles is not available in the provided context. However, as CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the rapidly evolving digital healthcare market in China.
Erfolgsbilanz: Specific achievements and milestones under Difan Shen's leadership are not detailed in the provided context. As CEO, he is responsible for driving the company's growth and profitability, expanding its service offerings, and navigating the complex regulatory landscape in China.
Alibaba Health Information Technology Limited ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ALBBY is an ADR that allows U.S. investors to invest in Alibaba Health Information Technology Limited without directly purchasing shares on the Hong Kong Stock Exchange. The ADR represents a specific number of underlying ALBB shares.
- Heimatmarkt-Ticker: Hong Kong Stock Exchange (ALBB), Hong Kong
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: ALBB
ALBBY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited or no financial disclosure requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Affiliation with Alibaba Group.
- Established presence in the Chinese healthcare market.
- Operation of online and offline pharmacies.
- Provision of digital healthcare services.
ALBBY Healthcare Aktien-FAQ
What are the key factors to evaluate for ALBBY?
Alibaba Health Information Technology Limited (ALBBY) currently holds an AI score of 46/100, indicating low score. Key strength: Strong brand recognition and reputation.. Primary risk to monitor: Potential: Changes in government regulations regarding online pharmacies and healthcare services.. This is not financial advice.
How frequently does ALBBY data refresh on this page?
ALBBY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALBBY's recent stock price performance?
Recent price movement in Alibaba Health Information Technology Limited (ALBBY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition and reputation.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALBBY overvalued or undervalued right now?
Determining whether Alibaba Health Information Technology Limited (ALBBY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALBBY?
Before investing in Alibaba Health Information Technology Limited (ALBBY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ALBBY to a portfolio?
Potential reasons to consider Alibaba Health Information Technology Limited (ALBBY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong brand recognition and reputation.. Additionally: Integration with Alibaba's ecosystem.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ALBBY?
Yes, most major brokerages offer fractional shares of Alibaba Health Information Technology Limited (ALBBY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALBBY's earnings and financial reports?
Alibaba Health Information Technology Limited (ALBBY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ALBBY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.